Status:
UNKNOWN
Treatment of Refractory Gout With ACTH or Methylprednisolone
Lead Sponsor:
Shanghai 10th People's Hospital
Conditions:
Gout
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To clarify the therapeutic effect and safety evaluation of ACTH in refractory gouty arthritis and special population, and to explore its mechanism of action.
Detailed Description
When patients with acute gout have multiple comorbidities and complications , traditional treatment methods are often contraindicated . From the current clinical research evidence , we have seen the n...
Eligibility Criteria
Inclusion
- (123 items and 1 item from 4-7 are met simultaneously) :
- Meet the 2015 ACR/EULAR classification diagnostic criteria for gout
- Acute gouty arthritis
- Age ≥18
- Repeated attacks and prolonged pain (more than 1 month);
- poor response or intolerance to colchicine or NSAIDs;
- Liver and kidney dysfunction;
- Old age;
Exclusion
- 1\) History of gastrointestinal bleeding and active ulcer 2) The application history of glucocorticoids and ACTH in 1 month before screening 3) Pregnancy and lactation 4) Drug and alcohol abuse 5) Malignant tumor (treated or untreated within 5 years) 6) Mental illness inability to communicate or have language barriers and inability to fully understand and cooperate 7) negligent compensatory heart failure, unstable angina pectoris, stroke, transient ischemic attack, myocardial infarction, and severe arrhythmia occurred within 6 months 8) The investigator did not consider it appropriate to participate in the study
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04808856
Start Date
April 1 2021
End Date
April 1 2022
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Tenth People's hospital
Shanghai, Shanghai Municipality, China, 200070